Navigation Links
MIT aids creation of neural prosthetic devices
Date:10/3/2007

CAMBRIDGE, Mass.--MIT researchers have developed a new algorithm to help create prosthetic devices that convert brain signals into action in patients who have been paralyzed or had limbs amputated.

The technique, described in a paper published as the cover article in the October edition of the Journal of Neurophysiology, unifies seemingly disparate approaches taken by experimental groups that prototype these neural prosthetic devices in animals or humans.

The work represents an important advance in our understanding of how to construct algorithms in neural prosthetic devices for people who cannot move to act or speak, said Lakshminarayan Ram Srinivasan (MIT S.M., Ph.D. '06), lead author of the paper.

Srinivasan, currently a postdoctoral researcher at the Center for Nervous System Repair at Massachusetts General Hospital and a medical student in the Harvard-MIT Division of Health Sciences and Technology (HST), began working on the algorithm while a graduate student in MIT's Department of Electrical Engineering and Computer Science (EECS).

Both trauma and disease can lead to paralysis or amputation, reducing the ability to move or talk despite the capacity to think and form intentions. In spinal cord injuries, strokes, and diseases such as amyotrophic lateral sclerosis (Lou Gehrig's disease), the neurons that carry commands from the brain to muscle can be injured. In amputation, both nerves and muscle are lost.

Neural prosthetic devices represent an engineer's approach to treating paralysis and amputation. Here, electronics are used to monitor the neural signals that reflect an individual's intentions for the prosthesis or computer they are trying to use. Algorithms form the link between neural signals that are recorded, and the user's intentions that are decoded to drive the prosthetic device.

Over the past decade, efforts at prototyping these devices have divided along various boundaries related to
'/>"/>

Contact: Elizabeth Thomson
thomson@mit.edu
617-258-5402
Massachusetts Institute of Technology
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Molecular steps involved in the creation of gene-silencing microRNAs identified
2. K-State professors discover enzyme responsible for creation of a beetles hard shell
3. Creationism is not science ?making the case for Darwin at UCL
4. Twin molecular scissors link creation of microRNAs with gene-silencing
5. Creation of antibiotic in test tube holds promise for better antibiotics
6. Worlds leading scientists announce creation of Encyclopedia of Life
7. Gene keeps neural cells on correct developmental path
8. Researchers discover stem cell guide that may be key for targeting neural stem cell treatments
9. Gambling monkeys give insight into neural machinery of risk
10. Brain size may depend upon how neural cells are cleaved
11. Defect in gene causes neuralgic amyotrophy

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...heart pumps some 250 million liters of blood throu...ibers of the heart have to be extremely durable. T..., vice chair of the Department of Medicine III at .... H. A. Katus), has discovered a protein that is r...lar unit, the sarcomere. In cooperation with other...
(Date:11/24/2009)...prescribed by traditional healers in Brazil to tre...pain to fever and flu. , Now for the first time, ... to scientifically prove the pain relieving proper...lian mint. , Testing this ancient South American ...Rocha was able to show that when prepared as a ,te...
(Date:11/24/2009)...ein that may help gut bacteria bind to the gastroi...iotic producers to identify strains that are likel...need to interact with cells lining the gut to have...es in the gut they are more likely to stick around...halie Juge from the Institute of Food Research. I...
Breaking Biology News(10 mins):New genetic cause of cardiac failure discovered 2Got a pain? -- Have a cup of Brazilian mint 2A sticky solution for identifying effective probiotics 2Data Published in The New England Journal of Medicine Support Use of Raxibacumab 28ABthrax 28TM 29 29 for the Treatment of Inhalation Anthrax 12949 1Data Published in The New England Journal of Medicine Support Use of Raxibacumab 28ABthrax 28TM 29 29 for the Treatment of Inhalation Anthrax 12949 2Data Published in The New England Journal of Medicine Support Use of Raxibacumab 28ABthrax 28TM 29 29 for the Treatment of Inhalation Anthrax 12949 3Data Published in The New England Journal of Medicine Support Use of Raxibacumab 28ABthrax 28TM 29 29 for the Treatment of Inhalation Anthrax 12949 4Data Published in The New England Journal of Medicine Support Use of Raxibacumab 28ABthrax 28TM 29 29 for the Treatment of Inhalation Anthrax 12949 5Go Healthy Announces Negotiations With Bottling Facilities 51183 1Go Healthy Announces Negotiations With Bottling Facilities 51183 2Cepheid Schedules 2009 Second Quarter Financial Results Announcement and Webcast 12948 1Cepheid Schedules 2009 Second Quarter Financial Results Announcement and Webcast 12948 2
...ditions to come , Human-induced climate change i...titudes. To assess whether the onset of drier con...wly developed multicentury tree ring records from ...on drought in northwestern Africa. Using a new set...ntica) and Aleppo pines ( Pinus halepensis ), the ...
...ellow. Do you gun the engine and speed through the...their green, or do you slow down and wait your tur...lity, according to new research from Tel Aviv Univ...he Department of Zoology at Tel Aviv University, r...le adopt risk-taking behaviors similar to those of...
...stigating exactly how chemotherapy drugs kill canc...test the effectiveness of safer new agents. , Dr S...y of Manchester,s Faculty of Life Sciences have ta...otic drugs, which are used extensively for breast ...s, which includes the agent taxol, has been used c...
Other Biology News:AGU journal highlights -- August 6, 2008 2AGU journal highlights -- August 6, 2008 3AGU journal highlights -- August 6, 2008 4AGU journal highlights -- August 6, 2008 5AGU journal highlights -- August 6, 2008 6AGU journal highlights -- August 6, 2008 7Humans' response to risk can be unnecessarily dangerous, finds Tel Aviv University study 2How chemo kills tumors: research to reduce side effects 2How chemo kills tumors: research to reduce side effects 3
(Date:11/24/2009)..., CALGARY and BLENHEIM, Ontario, Nov. 24 /PRNews...ed today it is acquiring the assets of Hyland Seed...tario. The addition of Hyland Seeds will further e...the company anticipates the introduction of Smart...de Tolerant Trait Technology in corn in 2012. The ...
(Date:11/24/2009)... , REYKJAVIK, Iceland, November ... (Nasdaq: DCGN ) today announced the approval of a...cy Court for the District of Delaware,(the "Bankru...etition for,relief under Chapter 11 of the United ..., The orders issued by the Bankruptcy Cou...
(Date:11/24/2009)...SEATTLE,Nov.24/PRNewswire/--BlueMarbleEnergyCorp.a...opmentAuthority(OPDA)wererecentlyawarded$2millionb...oard(CERB)inaprivate/publicpartnershiptoconstructt...colnCounty,WA. ,, "Thisinvestmentwillsignifican...70greenjobstoLincolnCounty,"saidBlueMarbleEnergyCE...
(Date:11/24/2009)..., DUBLIN, November 24 /PRNewswire-FirstCall...obal specialty biopharmaceutical company, today,an...n Medicines Agency for,velaglucerase alfa, the com...or the treatment of Type 1 Gaucher disease. This i...e alfa that has been submitted, with previous,subm...
Breaking Biology Technology:Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 3deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4
...edic Imaging, PARIS and ATLANTA, Oct. 9 Biospace...arance from the Food and Drug Administration,(FDA)...nited States for 2D,imaging use. EOS 2D|3D techno...ging,allowing images to be obtained with a low dos...al imaging, permitting full-body, uninterrupted di...
...echnology company translating the complexity of hu..., today announced that Andrea Matthews,(age 25), m... Mass High,Tech for its "People to Watch Under 30....idual like Andrea as,part of our team," said Dr. K..."She has been a go-getter ever since she started a...
...ey, OAK BROOK, Ill. and CARY, N.C., Oct. 9 The U...ce of academic medical centers and,their affiliate...ent,technology and services for academic and resea...rship to provide organizations participating in,UH...a robust, easy-to-use,procurement engine to stream...
Other Biology Technology:FDA Clears Biospace med's Revolutionary Low Dose Xray Imager 2FDA Clears Biospace med's Revolutionary Low Dose Xray Imager 3FDA Clears Biospace med's Revolutionary Low Dose Xray Imager 4Genstruct's Andrea Matthews Selected for Mass High Tech's 'People to Watch Under 30' 2University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement 2University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement 3
10% BSA in TBS from Upstate
Rabbit Anti-Aortic Elastin Polyclonal Antibody, Unconjugated from Abcam
Anti-Mouse VEGF-C Antibody, Unconjugated from Raybiotech, Inc.
Rabbit Anti-MEF2A, phospho (Thr312) Antibody, Unconjugated from Spring Bioscience
Biology Products: